GlassScriptPhysician profile
Brooke Gillett
NPI 1356538003
$4,424.85
in general payments reported to CMS, 2019-2025
42 companies · $2,330 in 2025
The $2,330 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $104 · 2021: $223 · 2022: $237 · 2023: $276 · 2024: $852 · 2025: $2,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,425 · Consulting Fee: $769 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,424.95 |
| Consulting Fee | $768.50 |
| Education | $263.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $856.79 | 2021-2025 | Enhertu |
| Janssen Biotech, INC. | $469.23 | 2022-2025 | Erleada, Rybrevant, Carvykti |
| Pfizer INC. | $390.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $350.32 | 2022-2025 | Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $288.34 | 2021-2025 | Opdivo, Opdualag |
| Celgene Corporation | $251.57 | 2023-2025 | Reblozyl, Pomalyst |
| Stemline Therapeutics INC. | $163.06 | 2024-2025 | Orserdu |
| Novartis Pharmaceuticals Corporation | $123.34 | 2023-2025 | |
| Lilly USA, LLC | $118.51 | 2019-2025 | Verzenio, Jaypirca |
| Portola Pharmaceuticals, LLC | $98.89 | 2019 | |
| Sanofi-Aventis U.S. LLC | $93.95 | 2024 | |
| Epizyme, INC. | $91.91 | 2021 | |
| Genzyme Corporation | $83.82 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $81.68 | 2024-2025 | Keytruda, Lynparza |
| Beone Medicines USA, INC. | $79.30 | 2025 | Brukinsa, Tevimbra |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Gillett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.